重组人胰岛素注射液治疗糖尿病74例的临床分析

Clinical Analysis of Recombinant Human Insulin Injection in Treatment of 74 Patients with Diabetes

目的:观察重组人胰岛素注射液治疗糖尿病的临床疗效。方法:将148例确诊为糖尿病的患者随机分为对照组和观察组,每组74例。在常规治疗的基础上,对照组采用中效人胰岛素(诺和灵30R)进行治疗,观察组采用重组人胰岛素注射液(优泌林30R)进行治疗,比较两组治疗前后空腹血糖、餐后2 h血糖、糖化血红蛋白、总胆固醇、低密度脂蛋白胆固醇水平以及胰岛素抵抗指数等指标。结果:经过4个月治疗后,观察组和对照组的空腹血糖分别降低至(5.68±0.26)mmol/L和(6.83±0.41)mmol/L;餐后2 h血糖分别降低至(6.81±0.58)mmol/L和(8.83±0.43)mmoL/L;糖化血红蛋白分别降低至(5.38±0.17)%和(7.42±0.22)%。与治疗前比较,两组空腹血糖、餐后2 h血糖、糖化血红蛋白以及其他临床指标如总胆固醇、低密度脂蛋白胆固醇水平等均得到显著改善,差异有统计学意义(P<0.05),但观察组改善更加明显,与对照组比较,差异有统计学意义(P<0.05)。结论:重组人胰岛素注射液治疗糖尿病临床疗效显著,安全性较高,值得临床上推广应用。

Objective：To observe the clinical effect of recombinant human insulin injection in treatment of diabetes, to provide the experimental data and theoretical support for the future clinical work. Method：148 patients with diabetes were divided into control group and observation group randomly,74 cases in each group.On the basis of conventional treatment, the control group were treated with insulin（gnosis 30 r）,the observation group were treated with recombinant human insulin injection（optimal secrete Lin 30 r）.Fasting blood glucose before and after the treatment,2 h postprandial blood glucose, glycosylated hemoglobin,total cholesterol,low density ester protein,cholesterol and insulin resistance index and other indicators in two groups were compared. Result：After four months after treatment,the fasting blood glucose in observation group and control group were reduced to（5.68 ±0.26）mmol/L and（6.83±0.41）mmol/L;2 h blood glucose after meal in observation group and control group were reduced to（6.81±0.58）mmol/L and（8.83±0.43）mmol/L;glycosylated hemoglobin were reduced to（5.38±0.17）%and（7.42±0.22）%. Compared with before treatment,fasting blood glucose, 2 h postprandial blood glucose,glycosylated hemoglobin,and other clinical indicators such as total cholesterol,low density ester protein such as cholesterol levels of two groups were significantly improved,the difference was statistically significant（P〈0.05）,but the observation group improved more significantly,compared with control group,the difference was statistically significant（P〈0.05）.Conclusion：The clinical curative effect of recombinant human insulin injection in treatment of diabetes is distinct,high security,is worthy in clinical application.